{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:09:07Z","timestamp":1784891347717,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.psychres.2020.113285","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T23:19:42Z","timestamp":1594336782000},"page":"113285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement"],"prefix":"10.1016","volume":"291","author":[{"given":"Maju Mathew","family":"Koola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Looney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houlin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anilkumar","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psychres.2020.113285_bib0001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/smns.1995.0011","article-title":"Neuronal nicotinic receptors: function, modulation and structure","volume":"7","author":"Albuquerque","year":"1995","journal-title":"Semin. Neurosci."},{"issue":"Nov","key":"10.1016\/j.psychres.2020.113285_bib0002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.neuropharm.2014.08.015","article-title":"Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential","volume":"86","author":"Ahnaou","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psychres.2020.113285_bib0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuroscience.2013.01.063","article-title":"Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine","volume":"238","author":"Alexander","year":"2013","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.psychres.2020.113285_bib0004","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00213-011-2539-2","article-title":"Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine","volume":"220","author":"Alexander","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"issue":"Jul(1)","key":"10.1016\/j.psychres.2020.113285_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archinte.1956.00250250041006","volume":"98","author":"Altschule","year":"1956","journal-title":"AMA Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.psychres.2020.113285_bib0006","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.13507","article-title":"Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: cognitive and (electro) physiological responses","volume":"84","author":"Alvarez-Jimenez","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2-3","key":"10.1016\/j.psychres.2020.113285_bib0007","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.schres.2013.07.026","article-title":"Pharmacological approaches to treating negative symptoms: a review of clinical trials","volume":"150","author":"Arango","year":"2013","journal-title":"Schizophr. Res."},{"issue":"Jun 27(1)","key":"10.1016\/j.psychres.2020.113285_bib0008","doi-asserted-by":"crossref","first-page":"9324","DOI":"10.1038\/s41598-019-45796-7","article-title":"Facilitation and inhibition of firing activity and N-methyl-D-aspartate-evoked responses of CA1 hippocampal pyramidal cells by alpha7 nicotinic acetylcholine receptor selective compounds in vivo","volume":"9","author":"Bali","year":"2019","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.psychres.2020.113285_bib0009","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/ejn.12160","article-title":"Kynurenic acid, by targeting \u03b17 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo","volume":"37","author":"Beggiato","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.psychres.2020.113285_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2014.02.019","article-title":"Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex","volume":"82","author":"Beggiato","year":"2014","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2020.113285_bib0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/157488709788186021","article-title":"A general framework for the evaluation of clinical trial quality","volume":"4","author":"Berger","year":"2009","journal-title":"Rev. Recent Clin. Trial"},{"key":"10.1016\/j.psychres.2020.113285_bib0012","series-title":"Introduction to Meta-analysis","author":"Borenstein","year":"2009"},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0013","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/appi.ajp.2007.07050724","article-title":"Galantamine for the treatment of cognitive impairments in people with schizophrenia","volume":"165","author":"Buchanan","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.psychres.2020.113285_bib0015","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/schbul\/sbq038","article-title":"The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?","volume":"37","author":"Buchanan","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.psychres.2020.113285_bib0016","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0000000000000720","article-title":"A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia","volume":"37","author":"Buchanan","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.psychres.2020.113285_bib0017","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107 medications commonly used by older adults","volume":"56","author":"Chew","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.psychres.2020.113285_bib0018","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"5","key":"10.1016\/j.psychres.2020.113285_bib0019","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0006-3223(00)00918-5","article-title":"Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation","volume":"48","author":"Crook","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2020.113285_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"issue":"1-3","key":"10.1016\/j.psychres.2020.113285_bib0021","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2013.05.023","article-title":"Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy","volume":"148","author":"Deutsch","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1-3","key":"10.1016\/j.psychres.2020.113285_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2007.12.491","article-title":"High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia","volume":"102","author":"Dyer","year":"2008","journal-title":"Schizophr. Res."},{"issue":"Dec","key":"10.1016\/j.psychres.2020.113285_bib0023","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2017.03.034","article-title":"Cognitive burden of anticholinergic medications in psychotic disorders","volume":"190","author":"Eum","year":"2017","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2020.113285_bib0024","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuro.2007.11.004","article-title":"Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells","volume":"29","author":"Ezoulin","year":"2008","journal-title":"Neurotoxicology"},{"issue":"33","key":"10.1016\/j.psychres.2020.113285_bib0025","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1523\/JNEUROSCI.0932-17.2017","article-title":"Preferential disruption of prefrontal GABAergic function by nanomolar concentrations of the \u03b17nACh negative modulator kynurenic acid","volume":"37","author":"Flores-Barrera","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.psychres.2020.113285_bib0026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neuroscience.2015.09.022","article-title":"Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine 3-monoxygenase (KMO) deletion or galantamine","volume":"310","author":"Forrest","year":"2015","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0027","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia","volume":"38","author":"Freedman","year":"1995","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2020.113285_bib0028","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am. J. Psychiatry."},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0029","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-004-1794-x","article-title":"Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists","volume":"174","author":"Friedman","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2020.113285_bib0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nicl.2018.07.019","article-title":"Changes in electrophysiological markers of cognitive control after administration of galantamine","volume":"20","author":"Gascoyne","year":"2018","journal-title":"Neuroimage. Clin."},{"issue":"Aug 30(2)","key":"10.1016\/j.psychres.2020.113285_bib0031","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.brainresbull.2004.06.008","article-title":"Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120","volume":"64","author":"Giunta","year":"2004","journal-title":"Brain Res. Bull."},{"issue":"4","key":"10.1016\/j.psychres.2020.113285_bib0032","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s12640-017-9815-9","article-title":"Neuroprotective effects of galantamine on nerve agent-induced neuroglial and biochemical changes","volume":"33","author":"Golime","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.psychres.2020.113285_bib0033","doi-asserted-by":"crossref","unstructured":"Green, M.F., Kern, R.S., Braff, D.L., Mintz, J.2000. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \"right stuff\" Schizophr Bull. 26 (1): 119-36.","DOI":"10.1093\/oxfordjournals.schbul.a033430"},{"issue":"3","key":"10.1016\/j.psychres.2020.113285_bib0034","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/mol.107.035410","article-title":"Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes","volume":"72","author":"Gr\u00f8nlien","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.psychres.2020.113285_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2017.06.040","article-title":"Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia","volume":"191","author":"Hamilton","year":"2018","journal-title":"Schizophr. Res."},{"issue":"19","key":"10.1016\/j.psychres.2020.113285_bib0036","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.psychres.2020.113285_bib0037","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/jnnp-2012-302268","article-title":"Galantamine administration in chronic post-stroke aphasia","volume":"83","author":"Hong","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin. Trials."},{"issue":"10","key":"10.1016\/j.psychres.2020.113285_bib0039","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","article-title":"Schizophrenia is a cognitive illness: time for a change in focus","volume":"70","author":"Kahn","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2020.113285_bib0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40263-017-0428-x","article-title":"Managing negative symptoms of schizophrenia: how far have we come?","volume":"31","author":"Kantrowitz","year":"2017","journal-title":"CNS Drugs."},{"issue":"Jul(8)","key":"10.1016\/j.psychres.2020.113285_bib0041","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41386-020-0628-9","article-title":"Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients","volume":"45","author":"Kantrowitz","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"10.1016\/j.psychres.2020.113285_bib0042","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/npp.2015.176","article-title":"Randomized, double-blind, placebo-controlled study of encenicline, an \u03b17 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia","volume":"40","author":"Keefe","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2020.113285_bib0043","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","article-title":"Galantamine in frontotemporal dementia and primary progressive aphasia","volume":"25","author":"Kertesz","year":"2008","journal-title":"Dement Geriatr. Cogn. Disord."},{"issue":"Jun 5(3362)","key":"10.1016\/j.psychres.2020.113285_bib0044","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1126\/science.129.3362.1528","article-title":"Biochemical theories of schizophrenia","volume":"129","author":"Kety","year":"1959","journal-title":"I. Science."},{"issue":"Dec;17(12)","key":"10.1016\/j.psychres.2020.113285_bib0045","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1017\/S1461145714000613","article-title":"Galantamine promotes adult hippocampal neurogenesis via M\u2081 muscarinic and \u03b17 nicotinic receptors in mice","author":"Kita","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Sep 28","key":"10.1016\/j.psychres.2020.113285_bib0046","first-page":"172","article-title":"Nicotine, auditory sensory memory, and sustained attention in a human ketamine model of schizophrenia: moderating influence of a hallucinatory trait","volume":"3","author":"Knott","year":"2012","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.psychres.2020.113285_bib0047","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00213-011-2535-6","article-title":"Effects of \u03b17 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis","volume":"220","author":"Kohlhaas","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.psychres.2020.113285_bib0048","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.neuroscience.2010.05.052","article-title":"Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry","volume":"169","author":"Konradsson-Geuken","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.psychres.2020.113285_bib0049","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajp.2018.01.009","article-title":"Anticholinergics to treat antipsychotic-induced extrapyramidal symptoms: time to avoid this practice","volume":"31","author":"Koola","year":"2018","journal-title":"Asian J. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2020.113285_bib0050","first-page":"134","article-title":"Potential role of antipsychotic-galantamine-memantine combination in the treatment of positive, cognitive, and negative symptoms of schizophrenia","volume":"4","author":"Koola","year":"2018","journal-title":"Mol. Neuropsychiatry"},{"issue":"14","key":"10.1016\/j.psychres.2020.113285_bib0051","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1111\/bph.14329","article-title":"Galantamine is not a positive allosteric modulator of human \u03b14\u03b22 or \u03b17 nicotinic acetylcholine receptors","volume":"175","author":"Kowal","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2020.113285_bib0052","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/138920111794480589","article-title":"Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia","volume":"12","author":"Kucinski","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"2","key":"10.1016\/j.psychres.2020.113285_bib0053","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e3280117feb","article-title":"A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia","volume":"22","author":"Lee","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"Jan 30(2)","key":"10.1016\/j.psychres.2020.113285_bib0054","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cbi.2006.11.008","article-title":"Nicotinic component of galantamine in the regulation of amyloid precursor protein processing","volume":"165","author":"Lenzken","year":"2007","journal-title":"Chem. Biol. Interact."},{"issue":"Apr 3","key":"10.1016\/j.psychres.2020.113285_bib0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pnpbp.2017.01.001","article-title":"Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: a translational meta-analysis of rodent and human studies","volume":"75","author":"Lewis","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2020.113285_bib0056","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.schres.2017.10.016","article-title":"Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia","volume":"195","author":"Lewis","year":"2018","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2020.113285_bib0057","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/hbm.23107","article-title":"Abnormal salience signaling in schizophrenia: The role of integrative beta oscillations","volume":"37","author":"Liddle","year":"2016","journal-title":"Hum. Brain Mapp."},{"issue":"6","key":"10.1016\/j.psychres.2020.113285_bib0058","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/npp.2012.259","article-title":"A randomized exploratory trial of an \u03b1-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia","volume":"38","author":"Lieberman","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2020.113285_bib0059","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine\u2013a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Rev."},{"issue":"Sep 21(38)","key":"10.1016\/j.psychres.2020.113285_bib0060","doi-asserted-by":"crossref","first-page":"16661","DOI":"10.1073\/pnas.1007397107","article-title":"Axonal \u03b17 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons","volume":"107","author":"Lin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2-3","key":"10.1016\/j.psychres.2020.113285_bib0061","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2010.08.021","article-title":"Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia","volume":"125","author":"Lindenmayer","year":"2011","journal-title":"Schizophr. Res."},{"issue":"Apr 18(1)","key":"10.1016\/j.psychres.2020.113285_bib0062","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12974-018-1141-5","article-title":"Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice","volume":"15","author":"Liu","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0063","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/jpet.107.123109","article-title":"Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha-7 nicotinic receptors","volume":"322","author":"Lopes","year":"2007","journal-title":"J Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.psychres.2020.113285_bib0064","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/brb3.118","article-title":"Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity","volume":"3","author":"Lopes","year":"2013","journal-title":"Brain Behav."},{"key":"10.1016\/j.psychres.2020.113285_bib0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-3-642-45106-5_9","article-title":"BDNF and synaptic plasticity, cognitive function, and dysfunction","volume":"220","author":"Lu","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0066","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tox.2011.07.007","article-title":"Galantamine rescues lead-impaired synaptic plasticity in rat dentate gyrus","volume":"289","author":"Luo","year":"2011","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.psychres.2020.113285_bib0067","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.mcn.2006.08.011","article-title":"BDNF up-regulates alpha7 nicotinic acetylcholine receptor levels on subpopulations of hippocampal interneurons","volume":"33","author":"Massey","year":"2006","journal-title":"Mol. Cell Neurosci."},{"issue":"9","key":"10.1016\/j.psychres.2020.113285_bib0068","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hipo.20572","article-title":"Galantamine enhancement of long-term potentiation is mediated by calcium\/calmodulin-dependent protein kinase II and protein kinase C activation","volume":"19","author":"Moriguchi","year":"2009","journal-title":"Hippocampus"},{"issue":"2","key":"10.1016\/j.psychres.2020.113285_bib0069","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hipo.20902","article-title":"Cooperation between cholinergic and glutamatergic receptors are essential to induce BDNF-dependent long-lasting memory storage","volume":"22","author":"Navakkode","year":"2012","journal-title":"Hippocampus"},{"issue":"8","key":"10.1016\/j.psychres.2020.113285_bib0070","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41386-018-0066-0","article-title":"\u03b17 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia","volume":"43","author":"Neves","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2020.113285_bib0071","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.neuropharm.2015.07.034","article-title":"Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats","volume":"101","author":"Nikiforuk","year":"2016","journal-title":"Neuropharmacology"},{"issue":"Jun(6)","key":"10.1016\/j.psychres.2020.113285_bib0072","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00213-020-05495-y","article-title":"Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task","volume":"237","author":"Phenis","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"2-3","key":"10.1016\/j.psychres.2020.113285_bib0073","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000111562","article-title":"Brain-derived neurotropic factor\/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia","volume":"16","author":"Pillai","year":"2008","journal-title":"Neurosignals"},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0074","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.pra.0000442935.15833.c5","article-title":"Normalizing effects of EVP-6124, an \u03b1-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia","volume":"20","author":"Preskorn","year":"2014","journal-title":"J. Psychiatry Pract."},{"key":"10.1016\/j.psychres.2020.113285_bib0075","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.nicl.2015.08.005","article-title":"Abnormal visuomotor processing in schizophrenia","volume":"12","author":"Robson","year":"2015","journal-title":"Neuroimage. Clin."},{"issue":"Nov 29(11)","key":"10.1016\/j.psychres.2020.113285_bib0076","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1038\/tp.2016.239","article-title":"Elevated brain lactate in schizophrenia: a 7\u2009T magnetic resonance spectroscopy study","volume":"6","author":"Rowland","year":"2016","journal-title":"Trans. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2020.113285_bib0077","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors","volume":"305","author":"Samochocki","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.psychres.2020.113285_bib0078","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00002826-199114001-00002","article-title":"Pharmacological alleviation of combined cholinergic\/noradrenergic lesion-induced memory deficits in rats","volume":"14","author":"Santucci","year":"1991","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2020.113285_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)08675-4","article-title":"Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands","volume":"49","author":"Schrattenholz","year":"1996","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2020.113285_bib0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2006.04.006","article-title":"Galantamine improves cognition in schizophrenic patients stabilized on risperidone","volume":"60","author":"Schubert","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"Nov 17","key":"10.1016\/j.psychres.2020.113285_bib0081","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainres.2014.09.032","article-title":"Galanthamine, an acetylcholine inhibitor, prevents prepulse inhibition deficits induced by adolescent social isolation or MK-801 treatment","volume":"1589","author":"Shao","year":"2014","journal-title":"Brain Res."},{"issue":"11","key":"10.1016\/j.psychres.2020.113285_bib0082","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.clinph.2018.08.014","article-title":"An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds","volume":"129","author":"Simpraga","year":"2018","journal-title":"Clin. Neurophysiol."},{"issue":"Jul 22(2)","key":"10.1016\/j.psychres.2020.113285_bib0083","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neulet.2004.04.067","article-title":"Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation","volume":"365","author":"Sobrado","year":"2004","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.psychres.2020.113285_bib0084","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jnc.14907","article-title":"Does kynurenic acid act on nicotinic receptors? An assessment of the evidence","volume":"152","author":"Stone","year":"2020","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.psychres.2020.113285_bib0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ntr\/nty034","article-title":"Alpha7 nicotinic receptors as therapeutic targets in schizophrenia","volume":"21","author":"Tregellas","year":"2019","journal-title":"Nicotine. Tob. Res."},{"issue":"7","key":"10.1016\/j.psychres.2020.113285_bib0086","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/npp.2014.17","article-title":"A randomized, placebo-controlled study investigating the nicotinic \u03b17 agonist, RG3487, for cognitive deficits in schizophrenia","volume":"39","author":"Umbricht","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.psychres.2020.113285_bib0087","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"1-3","key":"10.1016\/j.psychres.2020.113285_bib0088","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.schres.2014.01.006","article-title":"Chronic and bedtime use of benztropine with antipsychotics: is it necessary?","volume":"153","author":"Wijegunaratne","year":"2014","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.psychres.2020.113285_bib0089","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bcp.2011.05.001","article-title":"Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations","volume":"82","author":"Williams","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"36","key":"10.1016\/j.psychres.2020.113285_bib0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/schbul\/sbq002","article-title":"Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia","author":"Wonodi","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"1-2","key":"10.1016\/j.psychres.2020.113285_bib0091","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12031-009-9235-2","article-title":"The astrocyte-derived alpha-7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex","volume":"40","author":"Wu","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.psychres.2020.113285_bib0092","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2019.05.019","article-title":"Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials","volume":"209","author":"Zheng","year":"2019","journal-title":"Schizophr. Res."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120311082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120311082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:48:31Z","timestamp":1759038511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178120311082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":92,"alternative-id":["S0165178120311082"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113285","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113285"}}